Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966142 · ClinicalTrials.gov registry record · NA
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Chronic Pain Trial)
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 1,048
- Enrollment target
NCT05966142: Completed NA study, sponsored by Duke University.
NCT05966142 is a NA study that has completed, run by Duke University. The registered enrollment target is 1,048 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05966142, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,048 participants
- Enrollment target
Study Summary
This study is comprised of three separate pharmacogenetic trials grouped into a single protocol due to similarities in the intervention, the hypotheses, and the trial design. The three trials are the Acute Pain Trial, the Chronic Pain Trial, and the Depression Trial. Participants can enroll in only one of the three trials. All three trials were registered on ClinicalTrials.gov under NCT04445792. In July 2023 each of the three treatment trials was registered under a separate NCT# and NCT04445792 was converted to a screening record per recent guidance on master protocol research programs (MPRPs). This record is specific to the Chronic Pain Trial within the ADOPT-PGx protocol. The Chronic Pain Trial is a prospective, multicenter, two arm randomized pragmatic trial. Participants meeting eligibility criteria will be randomly assigned to either immediate pharmacogenetic testing and genotype-guided opioid therapy (Intervention arm) or standard care with 6-month delayed pharmacogenetic testing (Control arm). The investigators will test the hypothesis that pharmacogenetic testing and genotype guided pain therapy improves pain control after surgery in participants who's body processes some pain medicines slower than normal.
Primary Outcome
The composite pain intensity score is derived from the 3-time PROMIS (Patient-Reported Outcomes Measurement Information System) pain intensity scale. Composite pain intensity score is the sum of the 3 questions and ranges from 3 (no pain) to 15 (intense pain). Change in composite pain intensity score ranges from -12 (change from the highest level of pain to the lowest level of pain) to 12 (change from the lowest level of pain to the highest level of pain).
Interventions
- OTHER Pharmacogenetic testing
- OTHER Clinical decisions support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,048 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2024-05-10 |
| Phase | NA |
What the finished NCT05966142 record still lists
NCT05966142 is an interventional study that assigns participants to a tested intervention. Its 1,048 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 2 interventions - of which Pharmacogenetic testing is the first listed.
NCT05966142 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05966142 about?
NCT05966142 is a clinical study titled "A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Chronic Pain Trial)". This study is comprised of three separate pharmacogenetic trials grouped into a single protocol due to similarities in the intervention, the hypotheses, and the trial design. The three trials are the Acute Pain Trial, the Chronic Pain Trial, and the Depression Trial. Participants can enroll in only ...
What is the current status of trial NCT05966142?
This trial is currently completed. It is a NA study. The enrollment target is 1,048 participants. The study started on 2021-02-24. Estimated completion is 2024-05-10.
What interventions are being tested in trial NCT05966142?
The interventions under investigation include: Pharmacogenetic testing (OTHER), Clinical decisions support (OTHER).
Who is sponsoring clinical trial NCT05966142?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05966142's enrollment target sits among peer trials
1,048 100th of 2000 higher than 1,901 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04505618 · 1,050 participants · NA
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
- NCT04511806 · 1,050 participants
Childhood Cancer Predisposition Study (CCPS)
- NCT05028972 · 1,050 participants · NA
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
- NCT05915377 · 1,050 participants · NA
Researching Efficient Approaches to Delirium Identification-Sustaining Effective Translation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI